Back

Outcomes of heart failure with preserved ejection fraction (HFpEF) in patients with and without cardiac amyloidosis: analysis from 2016-2019 national inpatient sample

29 August 2022 (17:15 - 18:00)
Organised by:
Congress Presentation Part of: A focus on cardiac amyloidosis Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Soumya Kambalapalli

McLaren Flint Hospital, Flint (United States of America)

7 More presentations in this session

Presentation thumbnail
Myocardial ischaemia in cardiac amyloidosis: a change of perspective
Doctor A. Ioannou (Greater London, GB)
Abstract Slides
Presentation thumbnail
Coronary flow reserve by PET 13N-ammonia in patients with hereditary transthyretin amyloidosis with and without cardiac involvement.
Doctor A. Comte de Alencar Neto (Sao Paulo, BR)
Abstract Slides
Presentation thumbnail
Sustained vasodilation after cold pressor test is an independent predictor of poor survival in primary AL amyloidosis.
Doctor E. Maneta (Salt Lake City, US)
Abstract Slides
Presentation thumbnail
Incidence and risk factors for pacemaker implantation in light chain and transthyretin cardiac amyloidosis
Doctor A. Porcari (London, GB)
Abstract Slides
Presentation thumbnail
Prognostic implications of clinical phenotype and severity of cardiac involvement in patients presenting with immunoglobulin light chain amyloidosis
Doctor A. Porcari (London, GB)
Abstract Slides

Access the full session

Session thumbnail
A focus on cardiac amyloidosis

The Event

Event poster

ESC Congress 2022

29 August 2022 17:15 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources